Market cap
₹46 Cr
Recently Viewed
Clear AllNSE: MANGALAM | BSE: 532637
₹28.35
₹0.55
(1.98%)
As on 28-Apr-2026IST
Market cap
₹46 Cr
Revenue (TTM)
₹238 Cr
P/E Ratio
--
P/B Ratio
0.4
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
₹-31 Cr
ROE
4.8 %
ROCE
8.6 %
Industry P/E
46.73
EV/EBITDA
74.7
Debt to Equity
0.6
Book Value
₹69.9
EPS
₹-19.5
Face value
10
Shares outstanding
15,828,248
CFO
₹279.28 Cr
EBITDA
₹349.67 Cr
Net Profit
₹104.97 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Mangalam Drugs
| 3.1 | -0.4 | -32.8 | -64.7 | -37.0 | -27.8 | 2.9 |
|
BSE Healthcare
| 2.6 | 5.0 | 8.0 | 6.4 | 25.0 | 13.8 | 11.1 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Mangalam Drugs
| -77.0 | 16.1 | -28.4 | 5.4 | -5.9 | 388.4 | -61.8 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Mangalam Drugs
|
28.4 | 45.8 | 238.4 | -30.9 | -7.1 | -22.4 | -- | 0.4 |
| 2,467.8 | 20,207.0 | 1,215.1 | 284.8 | 28.7 | 21.1 | 70.4 | 13.3 | |
| 705.2 | 17,470.9 | 5,092.5 | 545.5 | 15.9 | 14.1 | 32 | 3.9 | |
| 942.5 | 14,987.6 | 7,918.4 | 429.9 | 10.7 | 7.2 | 34.6 | 2.3 | |
| 1,094.1 | 19,596.4 | 4,560.2 | 1,544.6 | 35.1 | 19.2 | 12.6 | 2.2 | |
| 1,763.0 | 20,205.8 | 1,419.3 | 20.1 | 8.4 | 0.5 | 1005.2 | 3.5 | |
| 164.5 | 21,839.6 | 8,871.4 | -223.5 | 1.9 | -1.6 | -- | 2.8 | |
| 954.7 | 15,744.8 | 1,284.3 | 134.4 | -- | 30.7 | 117.2 | 12.9 | |
| 440.3 | 17,729.3 | 3,720.2 | 352.1 | 13.7 | 8.2 | 50.4 | 3.7 | |
| 1,417.3 | 23,027.6 | 3,151.0 | -10.0 | 8.4 | 2.5 | 1046.7 | 5.0 |
1 min read•By Research Desk
Mangalam Drugs & Organics Limited, together with its subsidiary, manufactures and sells active pharmaceutical ingredients (APIs) and intermediates in India. The company offers active pharmaceutical ingredients (API) products, including acyclovir,... amodiaquine, artemether, artesunate, bisoprolol fumarate, chloroquine phosphate, dihydroartemisinin, dolutegravir sodium, efavirenz, emtricitabine, etodolac, furosemide, hydroxychloroquine sulphate, lumefantrine, nimesulide, nitrofurantoin anhydrous and monohydrate, olanzapine, primaquine and piperaquine phosphate, pyrimethamine, pyronaridine tetraphosphate, sulfadoxine, tenofovir alafenamide hemifumarate, and tenofovir disoproxil fumarate. It also provides intermediates, such as 2-dibutylamino-1-(2,7-dichloro-9H-fluorine-4-yl)-ethanol; 4,6-dichloro-5-methoxy pyrimidine; 4,7 dichloroquinoline; ortho phenoxy methane sulfonanilide; tenofovir alafenamide base; and tenofovir disoproxil base. In addition, the company offers specialty chemicals comprising l(+)menthol; 2,3-dihydrophthalazine-1, 4-dione or phthalazine-1,4-dione; and 4-cynoethyl-2-methy phenol. Further, it manufactures organic and inorganic chemicals, and heavy chemicals. Additionally, it offers active pharmaceutical ingredients; and products covering various therapeutic areas comprising anti-malaria, anti-retroviral, anti-hypertensive, anti-inflammatory, anti-convulsant, anti-viral, anti-rheumatic arthritis agents, and anti-bacterial, as well as develops product for anti-hypertensive indications. Mangalam Drugs & Organics Limited was incorporated in 1972 and is based in Mumbai, India. Read more
Incorporated
1972
Chairman
Govardhan M Dhoot
Managing Director
Govardhan M Dhoot
Headquarters
Mumbai, Maharashtra
Website
Looking for more details about Mangalam Drugs And Organics Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The share price of Mangalam Drugs And Organics Ltd is ₹28.35 (NSE) and ₹28.91 (BSE) as of 28-Apr-2026 IST. Mangalam Drugs And Organics Ltd has given a return of -37.04% in the last 3 years.
Since, TTM earnings of Mangalam Drugs And Organics Ltd is negative, P/E ratio is not available.
The P/B ratio of Mangalam Drugs And Organics Ltd is 0.41 times as on 28-Apr-2026, a 89 discount to its peers’ median range of 3.71 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
17.48
|
0.83
|
|
2024
|
0.00
|
1.08
|
|
2023
|
121.95
|
1.02
|
|
2022
|
8.28
|
1.08
|
|
2021
|
5.62
|
1.20
|
The 52-week high and low of Mangalam Drugs And Organics Ltd are Rs 95.00 and Rs 22.80 as of 28-Apr-2026.
Mangalam Drugs And Organics Ltd has a market capitalisation of ₹ 46 Cr as on 28-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Mangalam Drugs And Organics Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.